News

If a crisis were to suddenly arise for your organization, would your people be ready to handle it?

While the introduction of the Health Insurance Marketplace plans in 2014 has accelerated the trend of more Americans with HDHPs, the number of such plans was already increasing before then.

Blue Cross Blue Shield of Michigan (BCBSM) is collaborating with the University of Michigan Health System, physician organizations and pharmacists across the state to team up pharmacists with patient care teams as part of a new initiative to help patients manage and comply with their medication plans.

A deeper dive into the proposed payer mergers reveals how they could impact market dynamics.

The latest specialty drug pricing debate centers around Daraprim for toxoplasmosis infections, the price of which skyrocketed 5,000% within a month.

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.

Christopher Kerns, MBA, managing director, Research and Insights, The Advisory Board Company, believes high-deductible health plans (HDHPs) will help foster high-value healthcare.

Here are seven tips healthcare leaders must keep in mind when speaking to the press.

Beyond the obvious training and work flow challenges associated with the ICD-10 transition, a whole host of challenges will arise as ICD-10 becomes the new reality.

HealthSpot’s telebooths, which are currently in more than 20 Rite-Aid stores, are changing how patients interact with healthcare. Find out how it works.

A recent study projects that U.S. employers may see minimal savings to overall healthcare costs resulting from the introduction of biosimilars to the U.S. market.

A coalition is opposing the Access to Quality Diabetes Education Act of 2015, saying it limits access to care. Here's why, and how the American Association of Diabetes Educators (AADE) is responding.

A recent report evaluates the "true cost" of the 340B program. Read the key findings.

While Affordable Care Act has created huge opportunities for payers, most of those opportunities cannot be leveraged to their full advantage using 20th century strategies.

While biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.

Joint FDA advisory committees voted 23-1 against approving Purdue Pharma’s immediate release opioid painkiller Avridi last week.

FDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.

Next time you are looking to hire a new executive assistant, find someone with these skills and attributes

FDA approved aspirin extended release capsules (Durlaza, New Haven Pharmaceuticals, Inc.) for the prevention of stroke and acute cardiac events.

Marketing experts stress that payers and providers must find new ways to communicate with these young patients. Here's how.

Canadian study shows certain ethnic groups face higher heart disease risk factors than they did a decade ago.

Kentucky Senate Bill 192 may fund substance abuse providers to thwart heroin epidemic.

An NIH-sponsored trial enrolled more than 9,300 participants ages 50 and older with high blood pressure. View the results.

The Obama administration has proposed new regulations to include gender identity under the umbrella banning sex discrimination in healthcare. Find out what this means for health plans.

The FDA has strengthened its warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density.

Despite the potential benefits PAs offer, significant challenges to fully integrating them remain.

Although prescription drug misuse is declining among teens, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to a new analysis.

Alynlam Pharmaceuticals and The Medicines Company reported positive initial results from their ongoing Phase 1 clinical trial with their injectable cholesterol-lowing drug, ALSN-PCSsc, at the ESC Congress 2015 held in London, August 29 – September 2.